Teva Pharmaceutical Industries Ltd (TEVA)

TEVA (NYSE:Drugs) EQUITY
$33.70
neg -0.27
-0.79%
Today's Range: 33.66 - 34.12 | TEVA Avg Daily Volume: 10,385,800
Last Update: 01/17/17 - 12:25 PM EST
Volume: 4,669,940
YTD Performance: -6.29%
Open: $34.05
Previous Close: $33.97
52 Week Range: $33.56 - $64.31
Oustanding Shares: 1,015,000,000
Market Cap: 34,479,550,000
6-Month Chart
TheStreet Ratings Grade for TEVA
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 8 10 10
Moderate Buy 1 1 2 2
Hold 9 8 5 4
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.19 2.00 1.68 1.59
Latest Dividend: 0.29
Latest Dividend Yield: 3.40%
Dividend Ex-Date: 12/01/16
Price Earnings Ratio: 6.74
Price Earnings Comparisons:
TEVA Sector Avg. S&P 500
6.74 19.60 0.00
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-23.28% -45.89% -18.01%
GROWTH 12 Mo 3 Yr CAGR
Revenue -3.10 0.00 -0.01
Net Income -47.50 -0.20 -0.06
EPS -48.90 -0.20 -0.06
Earnings for TEVA:
EBITDA 5.79B
Revenue 19.65B
Average Earnings Estimates
Qtr (12/16) Qtr (03/17) FY (12/16) FY (12/17)
Average Estimate $1.33 $n.a. $5.05 $5.03
Number of Analysts 1 0 2 2
High Estimate $1.33 $n.a. $5.05 $5.06
Low Estimate $1.33 $n.a. $5.04 $5.00
Prior Year $1.28 $1.18 $5.42 $5.05
Growth Rate (Year over Year) 3.91% n.a.% -6.92% -0.30%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
This pharma company is still making lots of money and its stock is too cheap to pass up.
Not much action in the markets since our last update with the major indices continuing to grind slightly higher as we try to close out a solid…
Drug giants with money to spend and a friendlier regulatory environment should spur deals.

Biotech Poised for Rebound Real Money Pro($)

If M&A picks up and Trump doesn't tweet about excessively high drug prices, there should be bounce.
If M&A picks up and Trump doesn't tweet about excessively high drug prices, there should be bounce.
We touched briefly on housing in our first post this morning. There are still some cheap home-building stocks if the housing market continues to improve, which I expect as I believe economic growth will pick up in 2017. I have done well with this segment of the market in 2016 and I still believe there is value here.

Stop Listening to 'The Market' Real Money Pro($)

Here are stocks with solid fundamentals at some of the best absolute entry points in years.
Wait for a bounce and then a retest before stepping up to buy.
Small-caps could also benefit from abating tax-loss selling.
'Milestone payments' could boost deal's $125 million announced price.

Columnist Conversations

This morning, Morgan Stanley reported solid results for Q4, ahead of estimates for both revenue and earnings. ...
See my Jan. 12, 2017 Real Money Pro article for details on my thought process regarding Chipotle Mexican Grill...
Right call by JPMorgan this morning. Stock has rallied off the December lows, propelled by signs CEO Steve Ell...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.